Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.2
Journals
JoF
Special Issues
Gut Mycobiome, 2nd Edition
share announcement

Gut Mycobiome, 2nd Edition

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 3224

Special Issue Editor

Dr. Mysore V Tejesvi

E-Mail Website
Guest Editor
Department of Ecology and Genetics, University of Oulu, Oulu, Finland
Interests: microbiome; mycobiome; antimicrobials; bacteriome; bacteria–fungal interaction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will be dedicated to the gut mycobiome and there are many distinct types of fungi in the human gut, all playing an important role in host health. The term “mycobiome” refers to the community of fungi present in the digestive system and recent advances in sequencing technology and computational biology have enabled us to catalogue its enormous diversity. Despite the fact that research on the gut mycobiome is still in its early stages, some findings have shown that it may play a significant role in host homeostasis and disease development. However, its particular mechanism of action remains mostly unknown and studied. This Special Issue attempts to examine recent breakthroughs in research on the gut mycobiome from many aspects. This includes studying the variety of gut fungi, as well as how the gut mycobiome influences host defense and the gut–brain axis. Furthermore, we discussed how diet may impact the gut mycobiome by regulating interactions between fungi and bacteria. The research of the gut mycobiome is fascinating and any new findings are welcome.

Dr. Mysore V Tejesvi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mycobiome
  • Candida
  • host–fungus interactions
  • fungal–bacterial interations
  • mycobiome and gut brain axis
  • mycobiome and fungal metabolites

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 3035 KiB  
Article
Gut Mycobiome in Atopic Dermatitis and in Overweight Young Children: A Prospective Cohort Study in Finland
by Petri Vänni, Jenni Turunen, Ville K. Äijälä, Vilja V. Tapiainen, Marika Paalanne, Tytti Pokka, Niko Paalanne, Mysore V. Tejesvi and Terhi S. Ruuska
J. Fungi 2024, 10(5), 333; https://doi.org/10.3390/jof10050333 - 4 May 2024
Viewed by 2036
Abstract
Gut bacterial alterations have been previously linked to several non-communicable diseases in adults, while the association of mycobiome is not well understood in these diseases, especially in infants and children. Few studies have been conducted on the association between gut mycobiome and non-communicable [...] Read more.
Gut bacterial alterations have been previously linked to several non-communicable diseases in adults, while the association of mycobiome is not well understood in these diseases, especially in infants and children. Few studies have been conducted on the association between gut mycobiome and non-communicable diseases in children. We investigated gut mycobiome composition using 194 faecal samples collected at birth, 6 months after birth, and 18 months after birth in relation to atopic dermatitis (AD) and overweight diagnoses at the age of 18 or 36 months. The mycobiome exhibited distinct patterns, with Truncatella prevalent in the meconium samples of both overweight and non-overweight groups. Saccharomyces took precedence in overweight cases at 6 and 18 months, while Malassezia dominated non-overweight samples at 6 months. Saccharomyces emerged as a consistent high-abundance taxon across groups that had dermatitis and were overweight. We found a weak association between gut mycobiome and AD at birth and overweight at 18 months when using machine learning (ML) analyses. In ML, unidentified fungi, Alternaria, Rhodotorula, and Saccharomyces, were important for classifying AD, while Saccharomyces, Thelebolus, and Dothideomycetes were important for classifying overweight. Gut mycobiome might be associated with the development of AD and overweight in children. Full article
(This article belongs to the Special Issue Gut Mycobiome, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

29 pages, 2306 KiB  
Review
Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease
by Bogdan Severus Gaspar, Oana Alexandra Roşu, Robert-Mihai Enache, Monica Manciulea (Profir), Luciana Alexandra Pavelescu and Sanda Maria Creţoiu
J. Fungi 2025, 11(5), 333; https://doi.org/10.3390/jof11050333 - 22 Apr 2025
Viewed by 374
Abstract
The gut mycobiome, the fungal component of the gut microbiota, plays a crucial role in health and disease. Although fungi represent a small fraction of the gut ecosystem, they influence immune responses, gut homeostasis, and disease progression. The mycobiome’s composition varies with age, [...] Read more.
The gut mycobiome, the fungal component of the gut microbiota, plays a crucial role in health and disease. Although fungi represent a small fraction of the gut ecosystem, they influence immune responses, gut homeostasis, and disease progression. The mycobiome’s composition varies with age, diet, and host factors, and its imbalance has been linked to conditions such as inflammatory bowel disease (IBD) and metabolic disorders. Advances in sequencing have expanded our understanding of gut fungi, but challenges remain due to methodological limitations and high variability between individuals. Emerging therapeutic strategies, including antifungals, probiotics, fecal microbiota transplantation, and dietary interventions, show promise but require further study. This review highlights recent discoveries on the gut mycobiome, its interactions with bacteria, its role in disease, and potential clinical applications. A deeper understanding of fungal contributions to gut health will help develop targeted microbiome-based therapies. Full article
(This article belongs to the Special Issue Gut Mycobiome, 2nd Edition)
►▼ Show Figures

Figure 1

42 pages, 1014 KiB  
Review
The Gut Mycobiome for Precision Medicine
by Islam El Jaddaoui, Sofia Sehli, Najib Al Idrissi, Youssef Bakri, Lahcen Belyamani and Hassan Ghazal
J. Fungi 2025, 11(4), 279; https://doi.org/10.3390/jof11040279 - 2 Apr 2025
Viewed by 573
Abstract
The human gastrointestinal tract harbors a vast array of microorganisms, which play essential roles in maintaining metabolic balance and immune function. While bacteria dominate the gut microbiome, fungi represent a much smaller, often overlooked fraction. Despite their relatively low abundance, fungi may significantly [...] Read more.
The human gastrointestinal tract harbors a vast array of microorganisms, which play essential roles in maintaining metabolic balance and immune function. While bacteria dominate the gut microbiome, fungi represent a much smaller, often overlooked fraction. Despite their relatively low abundance, fungi may significantly influence both health and disease. Advances in next-generation sequencing, metagenomics, metatranscriptomics, metaproteomics, metabolomics, and computational biology have provided novel opportunities to study the gut mycobiome, shedding light on its composition, functional genes, and metabolite interactions. Emerging evidence links fungal dysbiosis to various diseases, including inflammatory bowel disease, colorectal cancer, metabolic disorders, and neurological conditions. The gut mycobiome also presents a promising avenue for precision medicine, particularly in biomarker discovery, disease diagnostics, and targeted therapeutics. Nonetheless, significant challenges remain in effectively integrating gut mycobiome knowledge into clinical practice. This review examines gut fungal microbiota, highlighting analytical methods, associations with human diseases, and its potential role in precision medicine. It also discusses pathways for clinical translation, particularly in diagnosis and treatment, while addressing key barriers to implementation. Full article
(This article belongs to the Special Issue Gut Mycobiome, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop